摘要
少突胶质细胞是专门的中枢神经系统轴突髓鞘的胶质细胞。有髓鞘的轴突捆绑在一起形成了白质区并可以连接灰质区的脑细胞,对于快速,集成的神经沟通与认知功能,它是必不可少的。少突胶质细胞的生命周期对于新神经元髓鞘通过天然的磨损和撕裂的连接和修复是必不可少的。这是无数成年人少突胶质母细胞(OPs)的作用。值得注意的是,在老龄化的大脑中,存在白质萎缩以及髓鞘形成的减少,它可以加速老年痴呆症。老年痴呆症髓鞘丢失的根本原因没有得到解决,但它意味着OPs再生能力的降低。OPs的一个特点是,他们形成了神经胶质细胞的突触并通过一系列谷氨酸受体对由神经元释放的谷氨酸产生反应。提出了OPs谷氨酸能神经传递,从而调节其增殖和分化形成髓鞘少突胶质细胞。在这里,我们讨论了OPs中产生的老年痴呆和少突胶质细胞受损的一代,它们是谷氨酸能神经传递的退化证据,是髓鞘丢失和相关认知能力下降的主要特点。
关键词: 阿尔茨海默病;痴呆;谷氨酸;髓鞘少突胶质细胞;少突胶质细胞的母细胞;白质。
Current Alzheimer Research
Title:Decreased Regenerative Capacity of Oligodendrocyte Progenitor Cells (NG2-Glia) in the Ageing Brain: A Vicious Cycle of Synaptic Dysfunction, Myelin Loss and Neuronal Disruption?
Volume: 13 Issue: 4
Author(s): Andrea Rivera, Ilaria Vanzuli, Jose Julio Rodriguez Arellano and Arthur Butt
Affiliation:
关键词: 阿尔茨海默病;痴呆;谷氨酸;髓鞘少突胶质细胞;少突胶质细胞的母细胞;白质。
摘要: Oligodendrocytes are specialised glial cells that myelinate CNS axons. Myelinated axons are bundled together into white matter tracts that interconnect grey matter areas of the brain and are essential for rapid, integrated neuronal communication and cognitive function. Life-long generation of oligodendrocytes is required for myelination of new neuronal connections and repair of myelin lost through natural ‘wear and tear’. This is the function of a substantial population of adult oligodendrocyte progenitors (OPs). Notably, there is white matter shrinkage and decreased myelination in the ageing brain, which is accelerated in dementia. The underlying causes of myelin loss in dementia are unresolved, but it implies a decline in the regenerative capacity of OPs. A feature of OPs is that they form neuron-glial synapses and respond to glutamate released by neurons via a range of glutamate receptors. Glutamate neurotransmission onto OPs is proposed to regulate their proliferation and differentiation into myelinating oligodendrocytes. Here, we discuss evidence that deregulation of glutamate neurotransmission in dementia and compromised generation of oligodendrocytes from OPs are key features of myelin loss and associated cognitive decline.
Export Options
About this article
Cite this article as:
Andrea Rivera, Ilaria Vanzuli, Jose Julio Rodriguez Arellano and Arthur Butt , Decreased Regenerative Capacity of Oligodendrocyte Progenitor Cells (NG2-Glia) in the Ageing Brain: A Vicious Cycle of Synaptic Dysfunction, Myelin Loss and Neuronal Disruption?, Current Alzheimer Research 2016; 13 (4) . https://dx.doi.org/10.2174/1567205013666151116125518
DOI https://dx.doi.org/10.2174/1567205013666151116125518 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Endocannabinoid System in Neurological Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Mechanisms of CTLA-4-Ig in Tolerance Induction
Current Pharmaceutical Design Cannabinoids, Immune System and Cytokine Network
Current Pharmaceutical Design Transient Opening of the Blood-Brain Barrier by Vasoactive Peptides to Increase CNS Drug Delivery: Reality Versus Wishful Thinking?
Current Neuropharmacology Calpain Inhibition: A Therapeutic Strategy Targeting Multiple Disease States
Current Pharmaceutical Design Modulation of Regulatory T Cells in Health and Disease: Role of Toll-Like Receptors
Inflammation & Allergy - Drug Targets (Discontinued) Inflammation in Parkinsons Diseases and Other Neurodegenerative Diseases: Cause and Therapeutic Implications
Current Pharmaceutical Design The Prospect of Stem Cells as Multi-Faceted Purveyors of Immune Modulation, Repair and Regeneration in Multiple Sclerosis
Current Stem Cell Research & Therapy Basic Approaches in Therapy of Multiple Sclerosis (MS) and Related Diseases: Current Achievement and Prospective
Central Nervous System Agents in Medicinal Chemistry Experimental and Clinical Application of Plasmid DNA in the Field of Central Nervous Diseases
Current Gene Therapy Mesenchymal Stem Cells Targeting of Systemic Disorders in Age-related Macular Degeneration
Current Tissue Engineering (Discontinued) Preparation of Knockout Extract for Determination of Really Active Compound Using MAb
Current Drug Discovery Technologies Presentation of Lipid Antigens by CD1 Glycoproteins
Current Pharmaceutical Design S100A9 as a Pharmacological Target Molecule in Inflammation and Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial [Hot Topic:Metalloproteinases Revisited (Guest Editor: Marcia L. Moss)]
Current Pharmaceutical Biotechnology Molecular Targets to Promote Central Nervous System Regeneration
Current Neurovascular Research Chemotherapeutic Properties of n-3 Polyunsaturated Fatty Acids - Old Concepts and New Insights
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Advances in Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 1: Overview of the Chemical and Biological Research
Current Drug Targets Glutamate Receptors in Microglia
CNS & Neurological Disorders - Drug Targets Anti-Inflammatory Immunotherapy for Multiple Sclerosis/Experimental Autoimmune Encephalomyelitis (EAE) Disease
Current Medicinal Chemistry